Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.51 |
| ▸ | DRD2 | P14416 | 4/20 | 0.48 |
| ▸ | DRD3 | P35462 | 3/20 | 0.48 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6220245 | 0.83 | HDAC1 (0.56) | HDAC1PKMCYP1A1DRD2DRD3 | |
| SCHEMBL8471981 | 0.83 | HDAC1 (0.56) | HDAC1PKMCYP1A1DRD2DRD3 | |
| SCHEMBL3714292 | 0.83 | DRD2 (0.61) | HDAC1PKMCYP1A1DRD2DRD3 | |
| SCHEMBL10498437 | 0.81 | RAB9A (0.49) | HDAC1PKMCYP1A1DRD2DRD3 | |
| SCHEMBL14734297 | 0.81 | DRD2 (0.63) | HDAC1DRD2DRD3RAB9AKCNH2 | |
| SCHEMBL8913255 | 0.81 | HDAC1 (0.67) | HDAC1PKMRAB9APOLBMAPT | |
| SCHEMBL10498393 | 0.81 | CYP1A1 (0.64) | HDAC1CYP1A1DRD2DRD3 | |
| SCHEMBL14734298 | 0.80 | DRD2 (0.61) | HDAC1CYP1A1DRD2DRD3RAB9A | |
| SCHEMBL18937416 | 0.80 | RAB9A (0.69) | HDAC1PKMDRD2DRD3RAB9A | |
| SCHEMBL13179111 | 0.80 | RAB9A (0.55) | HDAC1PKMDRD2DRD3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053372-A1 | 5-HT RECEPTOR MODULATORS | CAMBRIDGE ENTERPRISE LIMITED | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053372-A1 | 5-HT RECEPTOR MODULATORS | HTR1B, HTR5A, HTR1A | HDAC1 2448/4885PKM 2443/4885CYP1A1 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.